Ida Emilie Steinmark, PhD | Apr 26, 2023 | 3 min read
In a bid to address safety concerns about immune reactions during treatment with CRISPR-based therapeutics, a new technique speeds up how quickly the body destroys the DNA-cutting enzyme Cas9.
Abcam’s new premium-grade bioactive proteins are highly-active growth factors and cytokines manufactured and designed to meet the specific needs of cell culture, including cell and gene therapy and regenerative medicine.
The antimalarial drug reduces the number of infected Vero and human brain microvascular endothelial cells—among other cell types—in culture, researchers report in a preprint.
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
With human research trials resulting in dozens of successful deliveries in the US and abroad, doctors move toward offering the surgery clinically, while working to learn all they can about uterine and transplant biology from the still-rare procedure.
The high-profile retractions of two COVID-19 studies stunned the scientific community earlier this year and prompted calls for reviews of how science is conducted, published, and acted upon. The warning signs had been there all along.
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.
Deep learning approaches in development by big players in the tech industry can be used by biologists to extract more information from the images they create.